Microbiome startup Seres Therapeutics expands Nestl é Health partnership

As microbiome startup Seres Therapeutics gets ready to bring its C. difficile treatment to the FDA, it has expanded its partnership with Nestl é Health, which is providing Seres with up to $500 million to commercialize the drug. $MCRB

Source: bizjournals.com Health Care:Physician Practices headlines - July 2, 2021 Category: American Health Authors: Rowan Walrath Source Type: news